Fulgent Genetics Presents Strong Phase 2 Data for Cancer Drug FID-007 at ASCO
FLGT sits 34% above its 52-week low of $13.46.
Summary
Fulgent Genetics announced updated, highly positive Phase 2 clinical trial data for its cancer drug FID-007 at the ASCO 2026 Annual Meeting, showing strong efficacy and a manageable safety profile in head and neck cancer.
Key Events · Product Development and Regulatory · FLGT
-
Strong Phase 2 Data Presented
Updated preliminary data for FID-007 in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) showed an objective response rate of 61.9%, median progression-free survival of 6.7 months, median duration of response of 7.4 months, and one-year overall survival of 63.4%.
-
Manageable Safety Profile
The combination of FID-007 with cetuximab demonstrated a manageable safety profile in the target patient population.
-
Phase 3 Study Planned
The company plans to advance FID-007 into a Phase 3 clinical study based on these encouraging results.
Analysis · FLGT · Industrial Applications And Services
This 8-K provides detailed, positive clinical data from the Phase 2 study of FID-007 in head and neck cancer, which was previously announced in a general sense. The specific metrics, including a 61.9% objective response rate and 6.7 months median progression-free survival in a difficult-to-treat patient population, are highly encouraging and support the company's plan for a Phase 3 study. This significantly de-risks the therapeutic pipeline and reinforces the company's strategic shift towards precision medicine.
At the time of this filing, FLGT was trading at $18.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $513.8M. The 52-week trading range was $13.46 to $31.04. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.